Developing a new 3D printing technology for making advanced vaccines against influenza and other infectious diseases.
Official title: A Novel First-in-class 3D Printing Technology for Advanced Manufacturing of Complex Vaccine Formulations against Influenza and Emerging Infectious Diseases
Funded at University of Mississippi · NIH-11046367 · Data updated 2026-11-12
This study is exploring a new way to use 3D printing to make vaccines, especially for flu and other infectious diseases, by using yeast to produce the proteins needed for these vaccines more easily and affordably, so we can respond better to health needs around the world.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Mississippi NIH-funded |
| Lab location | 1 site (University, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $498,119 |
| NIH project number | 7R01FD007456-04 |
| Project ID | NIH-11046367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals at risk for influenza and other emerging infectious diseases, particularly during outbreaks.
✕Less likely to help
Patients who are not at risk for infectious diseases or those who have contraindications to vaccination may not benefit from this research.
What this research studies
This research focuses on creating a novel 3D printing technology to manufacture complex vaccine formulations, particularly targeting influenza and emerging infectious diseases. By utilizing recombinant DNA technology, the project aims to produce recombinant protein subunit vaccines more efficiently and cost-effectively. The approach involves using yeast expression systems to generate high quantities of the necessary proteins, which can then be purified and formulated into vaccines. This innovative method seeks to address the current limitations in vaccine production processes, making them more flexible and responsive to global health needs.
Why it matters
Potential benefit: If successful, this research could lead to faster and more efficient vaccine production, improving public health responses to infectious disease outbreaks.
How similar studies have gone: While the approach of using 3D printing for vaccine production is innovative, similar technologies in recombinant protein production have shown promise in other contexts.
Where this research is happening
-
University of Mississippi
University, United States Active
Researchers
- Principal investigator: Maniruzzaman, Mohammed — University of Mississippi
- Study coordinator: Maniruzzaman, Mohammed
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.